Iterum Therapeutics plc — Director's Dealing 2020

Apr 10, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2020-04-07

Reporting Person: Chin Mark (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-07	Ordinary Shares	J	1089903	—	Disposed	0	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-07	6.500% Exchangeable Senior Subordinated Note due 2025	$	J		Disposed	2025-01-31	Ordinary Shares (1900000)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	6154	Direct

Footnotes

F1: On April 7, 2020, the reporting person resigned as an investment director for Arix Bioscience plc, which is the sole owner and parent of Arix Bioscience Holdings Ltd., which holds these securities. As a result of his resignation, the reporting person no longer has any voting power over these securities and therefore has ceased to beneficially own such securities.

F2: Arix Bioscience Holdings Ltd. continues to hold these securities.